Sight Diagnostics® Expands to the Gulf Region through a Distribution Partnership with Phoenix Capital
Sight Diagnostics, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, announced a distribution partnership with Phoenix Capital to extend Sight’s footprint in the Middle East. Through the partnership, Sight will provide OLO analyzers – the company’s decentralized, lab-quality diagnostic technology – to medical centers across the Middle East to help providers make quick and informed treatment decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005496/en/
Sight OLO (Photo: Business Wire)
Most outpatient clinics in the United Arab Emirates are currently operating mini-labs with legacy diagnostic technologies like flow cytometry, which require large, expensive machines that aren’t suited for point-of-care (POC) settings. As such, there is an increasing demand for modern POC diagnostics in the Middle East and Africa, with the market projected to reach $2.85 billion by 2024.
Sight OLO enables fast, accurate, convenient blood diagnostics by delivering CBC results in minutes right at the point-of-care*. About the size of a toaster oven, OLO is small, compact, and light-weight, allowing for quick, simple set-up wherever it’s needed. Unlike traditional CBC analyzers, Sight OLO does not require reagents or manual quality control checks, making it easy for smaller clinics or independent practices to access and operate.
Abdullah Saeed Al Naboodah, Chairman of Phoenix Capital remarks, “We chose Sight OLO because it simply meets the needs of the clinics we distribute to. With the influx of patients due to COVID-19, having access to fast, accurate fingerprick diagnostics is essential to quickly and correctly triage and treat our clinic’s patients.”
Phoenix Capital will first distribute Sight OLO to the nine medical centers it owns across the United Arab Emirates. Over the next year, Sight will work with Phoenix Capital to start expanding OLO’s install base in the rest of the Gulf Cooperation Council region.
“We’re determined to democratize access to rapid, accurate, and convenient diagnostics in countries around the world,” says Yossi Pollak, CEO and Cofounder of Sight Diagnostics. “We’re looking forward to expanding into this new market through our partnership with Phoenix Capital to help meet the needs of emergency rooms, clinics, hospitals, and other care facilities that have been impacted by COVID-19.”
This distribution partnership follows a recent investment partnership between Phoenix Capital and OurCrowd, one of Sight’s longtime investors that recently participated in the diagnostic company’s $71 million Series D funding round. Notably, the news also follows a historic normalization agreement between Israel and the United Arab Emirates, signaling the countries’ progress in sharing resources and technology to improve healthcare together.
*Sight OLO received regulatory approval for use in the UAE and is CE Marked according to the IVD European directive at point of care settings. In the United States, Sight OLO is 510(k) cleared for use in moderate complexity laboratories; it has not yet been cleared for point-of-care use.
About Sight Diagnostics
Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing. Sight’s technology, developed over almost a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes. It’s compact: designed to be used in a variety of settings. Sight OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, ParasightTM, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the UK, the US and Israel. Learn more at www.SightDX.com.
About Phoenix Capital
Phoenix Capital was established by Mr Abdullah Al Naboodah to help catalyze the growth of expansion-seeking entrepreneurs and businesses from around the globe and to help create a more developed and connected world. By leveraging experiences in a diverse array of industries, Phoenix Capital’s portfolio of sophisticated and wide-ranging clients and partners serve as a springboard for entities with ambition to penetrate the GCC (Gulf Cooperation Council).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005496/en/
Contact information
Emma Baron
Senior Account Executive
VSC for Sight Diagnostics
sight@vsc.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
China’s Top Baijiu Brand Moutai Showcases China's Green Progress in Manufacturing at COP3015.11.2025 18:41:00 EET | Press release
On November 10 local time, the 30th United Nations Climate Change Conference (COP30) opened in Belem, a city in northern Brazil. As one of the activities at the China Pavilion of COP30, the Side Event on Ecological Civilization and Beautiful China Practice was held simultaneously, focusing on ecological civilization, sharing China's experience, and building global consensus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114596036/en/ China Pavilion at COP30 in Belem, Brazil. Addressing the topic of green transformation in traditional industries, You Yalin, Deputy Party Secretary of Kweichow Moutai Co., Ltd., shared the company's green transformation practices and experiences from the perspective of a traditional Chinese liquor producer. “We hope that every bottle of Moutai not only delivers a feast of flavor, but also conveys the idea of harmony between humans and nature. We aim to contribute China's wisdom and Moutai's
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom